More than 90% of patients
who started SPINRAZA,
remain on SPINRAZA.1*

Like Lauren.

*Based on commercial patients in the US (including Puerto Rico ) through December 2019.
Individual results may vary based on several factors, including severity
of disease, initiation of treatment, and duration of therapy.

More than 40% of people treated with SPINRAZA
are adults.1*

Like Ian.

*Based on commercial patients in the US (including Puerto Rico ) through December 2019.
Individual results may vary based on several factors, including severity
of disease, initiation of treatment, and duration of therapy.

More than 2900 people have been treated with SPINRAZA.1*

Like Sofia.

*Based on commercial patients in the US (including Puerto Rico ) through December 2019.
Individual results may vary based on several factors, including severity
of disease, initiation of treatment, and duration of therapy.

10000+ children and adults with spinal muscular atrophy (SMA)
have been treated with SPINRAZA worldwide.1†

Based on commercial patients, early access patients, and clinical trial participants as of  December 2019.

 

Find a treatment center near you

Use this Locator Tool to help find a treatment center near you that might be able to administer SPINRAZA.
 

Getting started with SPINRAZA

Once you and your patient have decided to begin treatment, submit a Start Form to enroll your patient in Biogen support services.

How does SPINRAZA work?

Watch the MOA video to learn how SPINRAZA increases the production of full-length survival motor neuron (SMN) protein.

Depending on your method of procurement, the Start Form may be used as a prescription.

The SPINRAZA clinical trials included
>350 individuals with SMA, ranging from
ages 3 days to 16 years at first dose.1

Clinical trial results

Get a closer look at the study results across a broad range of individuals with SMA.

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.
 

Available resources for you and your patients

PATIENT MOA VIDEO

Help them learn about the MOA from Emma, a patient treated with SPINRAZA.

SMA360°™

Biogen’s SMA360° support program provides services for patients and their families that address nonmedical barriers to access.

REIMBURSEMENT

A comprehensive guide to reimbursement considerations for SPINRAZA.
 

Stay connected

Sign up to receive the latest news, support information, and upcoming events.

Enter a valid email address

 

Reference

1. Data on file. Biogen, Cambridge, MA.